PT1330451E - Benzimidazol-2-onas substituídas como antagonistas do receptor da vasopressina e moduladores do neuropéptido y - Google Patents
Benzimidazol-2-onas substituídas como antagonistas do receptor da vasopressina e moduladores do neuropéptido y Download PDFInfo
- Publication number
- PT1330451E PT1330451E PT01989314T PT01989314T PT1330451E PT 1330451 E PT1330451 E PT 1330451E PT 01989314 T PT01989314 T PT 01989314T PT 01989314 T PT01989314 T PT 01989314T PT 1330451 E PT1330451 E PT 1330451E
- Authority
- PT
- Portugal
- Prior art keywords
- neuropeptide
- modulators
- ones
- receptor antagonists
- vasopressin receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24381700P | 2000-10-27 | 2000-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1330451E true PT1330451E (pt) | 2008-03-13 |
Family
ID=22920251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT01989314T PT1330451E (pt) | 2000-10-27 | 2001-10-23 | Benzimidazol-2-onas substituídas como antagonistas do receptor da vasopressina e moduladores do neuropéptido y |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1330451B1 (pt) |
JP (1) | JP2004517872A (pt) |
AT (1) | ATE384711T1 (pt) |
AU (1) | AU2002243419A1 (pt) |
DE (1) | DE60132611T2 (pt) |
DK (1) | DK1330451T3 (pt) |
ES (1) | ES2300376T3 (pt) |
PT (1) | PT1330451E (pt) |
WO (1) | WO2002055514A2 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4839374B2 (ja) * | 2005-07-21 | 2011-12-21 | エフ.ホフマン−ラ ロシュ アーゲー | V1a受容体アンタゴニストとしてのインドール−3−イル−カルボニル−ピペリジン−ベンゾイミダゾール誘導体 |
WO2008025736A1 (en) | 2006-08-26 | 2008-03-06 | Abbott Gmbh & Co. Kg | Substituted benzimidazolone derivatives, medicaments comprising them and their use |
US9238658B2 (en) | 2011-12-06 | 2016-01-19 | Janssen Pharmaceutica Nv | Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors |
WO2013085957A1 (en) | 2011-12-06 | 2013-06-13 | Janssen Pharmaceutica Nv | Substituted piperidinyl-pyridazinyl derivatives useful as scd 1 inhibitors |
EA201690179A1 (ru) * | 2013-08-19 | 2016-06-30 | Ф. Хоффманн-Ля Рош Аг | Антагонисты рецептора v1a для лечения расстройств, связанных со сдвигом фазы сна |
JP7426939B2 (ja) * | 2018-03-01 | 2024-02-02 | トーマス・ヘレデイズ・スティフテルス・フォー・メディシンスク・フォルスクニング | 置換ベンゾジアゾールおよび療法におけるその使用 |
WO2022250108A1 (ja) * | 2021-05-26 | 2022-12-01 | 住友ファーマ株式会社 | フェニルウレア誘導体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3318900A (en) * | 1964-05-06 | 1967-05-09 | Janssen Pharmaceutica Nv | Derivatives of benzimidazolinyl piperidine |
JPH09500134A (ja) * | 1993-07-16 | 1997-01-07 | メルク エンド カンパニー インコーポレーテッド | ベンゾオキサジノンおよびベンゾピリミジノンピペリジニル早産防止オキシトシン受容体拮抗剤 |
US6057338A (en) * | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
WO1999052875A1 (en) * | 1998-04-08 | 1999-10-21 | Takeda Chemical Industries, Ltd. | Amine compounds, their production and their use as somatostatin receptor antagonists or agonists |
AU6211499A (en) * | 1998-09-30 | 2000-04-17 | Merck & Co., Inc. | Benzimidazolinyl piperidines as cgrp ligands |
GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
-
2001
- 2001-10-23 PT PT01989314T patent/PT1330451E/pt unknown
- 2001-10-23 DK DK01989314T patent/DK1330451T3/da active
- 2001-10-23 JP JP2002556183A patent/JP2004517872A/ja active Pending
- 2001-10-23 AT AT01989314T patent/ATE384711T1/de not_active IP Right Cessation
- 2001-10-23 ES ES01989314T patent/ES2300376T3/es not_active Expired - Lifetime
- 2001-10-23 AU AU2002243419A patent/AU2002243419A1/en not_active Abandoned
- 2001-10-23 WO PCT/US2001/051108 patent/WO2002055514A2/en active IP Right Grant
- 2001-10-23 DE DE60132611T patent/DE60132611T2/de not_active Expired - Fee Related
- 2001-10-23 EP EP01989314A patent/EP1330451B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2300376T3 (es) | 2008-06-16 |
WO2002055514A3 (en) | 2002-11-21 |
WO2002055514A2 (en) | 2002-07-18 |
JP2004517872A (ja) | 2004-06-17 |
ATE384711T1 (de) | 2008-02-15 |
EP1330451A2 (en) | 2003-07-30 |
DE60132611D1 (de) | 2008-03-13 |
DK1330451T3 (da) | 2008-11-10 |
EP1330451B1 (en) | 2008-01-23 |
DE60132611T2 (de) | 2009-02-19 |
AU2002243419A1 (en) | 2002-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY135688A (en) | Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide y modulators | |
SE0103644D0 (sv) | Therapeutic isoquinoline compounds | |
WO2002055012A3 (en) | Therapeutic heterocyclic compounds | |
SE0103649D0 (sv) | Therapeutic quinoline compounds | |
CA2379640A1 (en) | Certain alkylene diamine-substituted heterocycles | |
GEP20105073B (en) | Imidazo- and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i | |
SE0103648D0 (sv) | Therapeutic quinolone compounds | |
FI920217A0 (fi) | Angiotensin ii receptor blockerande 2,3,6-substituerade kinazolinoner. | |
NO20032861L (no) | Heteroarylurea nevropeptid Y Y5-reseptorantagonister | |
CA2469813A1 (en) | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | |
EA200600315A1 (ru) | Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения | |
WO2003053922A3 (en) | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 | |
PT1330451E (pt) | Benzimidazol-2-onas substituídas como antagonistas do receptor da vasopressina e moduladores do neuropéptido y | |
ATE362473T1 (de) | 1,5-disubstituierte 3,4-dihydro-1h-4,5- döpyrimidin-2-on-verbindungen und ihre verwendung in der behandlung von durch csbp/p38 kinase beeinflussten krankheiten | |
EA200300064A1 (ru) | Карбоксамидные соединения и их применение в качестве антагонистов 11cby-рецептора человека | |
TWI316057B (en) | Nonpeptide substituted spirobenzoazepines as vasopressin antagonists | |
WO2001004139A3 (en) | Human axor29 receptor | |
RS20050930A (en) | Substituted spirobenzazepines | |
HRP20080587T3 (en) | Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity | |
ATE330605T1 (de) | Piperidin-2,6-dionpamoat-salze und ihre verwendung zur behanldung von stressbedingten affektiven st rungen | |
PT1373218E (pt) | Derivados de imidazolilo úteis como ligandos do receptor h3 de histamina | |
Kozai et al. | Synthesis and hypnotic activities of 4-thio analogues of N3-substituted uridines | |
SE0103647D0 (sv) | Therapeutic chromone compounds | |
WO2006049984A3 (en) | Novel [1,4]benzodiazepines as vasopressin v2 receptor antagonists | |
WO2000071533A3 (en) | 1,4-dithiin and 1,4-dithiepin- 1,1,4,4, tetroxide derivatives useful as antagonists of the human galanin receptor |